<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01470742</url>
  </required_header>
  <id_info>
    <org_study_id>2010-04-118</org_study_id>
    <nct_id>NCT01470742</nct_id>
  </id_info>
  <brief_title>Trial Comparing Capecitabine Plus Oxaliplatin (XELOX) and Capecitabine (X) as First-line Chemotherapy in Elderly Patients With Advanced Gastric Cancer</brief_title>
  <official_title>A Randomized, Phase III, Multicenter Clinical Trial Comparing Capecitabine Plus Oxaliplatin (XELOX) and Capecitabine (X) as First-line Chemotherapy in Elderly Patients With Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the trial is to compare Overall survival between capecitabine plus
      oxaliplatin (XELOX) and capecitabine (X) as first-line chemotherapy in elderly patients with
      advanced gastric cancer.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival of XELOX(XELODA/oxaliplatin) vs X(XELODA)</measure>
    <time_frame>36months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>36months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>XELODA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capecitabine 1000mg/m2 bid D1-14 every 3weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XELOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D1-14 Capecitabine 1000mg/m2 bid D1 Oxaliplatin 110mg/m2 + D5W 250ml over 2hr every 3weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XELOX</intervention_name>
    <description>D1-14 Capecitabine 1000mg/m2 bid D1 Oxaliplatin 110mg/m2 + D5W 250ml over 2hr every 3weeks</description>
    <arm_group_label>XELOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XELODA</intervention_name>
    <description>Capecitabine 1000mg/m2 bid D1-14 every 3weeks</description>
    <arm_group_label>XELODA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 70

          2. Histologically or cytologically confirmed adenocarcinoma of the gastric

          3. Advanced ,metastatic/recurrence gastric cancer

          4. ECOG performance status of 0 to 2

          5. Life expectancy≥3months

          6. No history of any systemic anti-cancer chemotherapy (prior adjuvant chemoradiation or
             chemotherapy is allowed if the last date of drug administration is &gt; 6months from the
             study entry date)

          7. No history of radiation therapy about Target lesion. (Prior radiotherapy is permitted
             if it was not administered to target lesions selected for this study, unless
             progression of the selected target lesions within the radiation portal is documented,
             and provided it has been completed at least 4 weeks before randomization.

          8. Adequate marrow functions (ANC ≥ 1,500/uL, PLT ≥100,000/uL)

          9. Adequate renal functions (Creatinine ≤1.5mg/dL or Ccr ≥ 50ml/min)

         10. Adequate hepatic functions ( bilirubin ≤ 2.0mg/dL, SGOT/SGPT &lt; normal x 3)

         11. provision of a signed written informed consent

        Exclusion Criteria:

          1. History of any medical or psychiatric condition

          2. Active infections

          3. Peripheral neuropathy with symptom(NCI-CTCAE ver. 3.0 &gt;=Grade 1 )

          4. symptomatic brain metastases

          5. Double primary cancer (physician at the discretion of the other cancer cured the
             purpose of early cancer cases can be registered)

          6. History of other malignancy except:

             Adequately treated non-melanomatous skin cancer or cervical carcinoma in situ

          7. Known hypersensitivity to Fluoropyrimidines/platinum

          8. Clinical significant cardiovascular disease (myocardial infarction, symptomatic
             coronary artery disease, congestive heart failure, severe arrhythmias)

          9. Required immunosuppressive therapy(transplant patients, severe autoimmune disease)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2011</study_first_submitted>
  <study_first_submitted_qc>November 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2011</study_first_posted>
  <last_update_submitted>April 30, 2015</last_update_submitted>
  <last_update_submitted_qc>April 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Won Ki Kang</investigator_full_name>
    <investigator_title>Professor of Medicine, Sungkyunkwan University School of Medicine, Department of Hematology and Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

